BACKGROUND: Rectal cancer accounts for approximately one third of all colorectal cancers (CRC), which belong among leading causes of cancer deaths worldwide. Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection. Unfortunately, a significant proportion of tumors do not respond enough to the neoadjuvant treatment and these patients are at risk of relapse. MicroRNAs (miRNAs) are small non-coding RNAs playing significant roles in the pathogenesis of many cancers including rectal cancer. MiRNAs could present the new predictive biomarkers for rectal cancer patients. METHODS: We selected 20 patients who underwent neoadjuvant chemoradiotherapy for advanced rectal cancer and whose tumors were classified as most sensitive or resistant to the treatment. These two groups were compared using large-scale miRNA expression profiling. RESULTS: Expression levels of 8 miRNAs significantly differed between two groups. MiR-215, miR-190b and miR-29b-2* have been overexpressed in non-responders, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a* have shown higher expression levels in responders. Using these miRNAs 9 of 10 responders and 9 of 10 non-responders (p < 0.05) have been correctly classified. CONCLUSIONS: Our pilot study suggests that miRNAs are part of the mechanisms that are involved in response of rectal cancer to the chemoradiotherapy and that miRNAs may be promising predictive biomarkers for such patients. In most miRNAs we identified (miR-215, miR-99a*, miR-196b, miR-450b-5p and let-7e), the connection between their expression and radioresistance or chemoresistance to inhibitors of thymidylate synthetase was already established.

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Zluty kopec 7 Brno 656 53 Czech Republic

Zobrazit více v PubMed

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] International Agency for Research on Cancer, Lyon, France; 2010. Available from: http://globocan.iarc.fr, accessed on 29/07/2012.

Dusek L, Muzík J, Gelnarová E, Fínek J, Vyzula R, Abrahámová J. Cancer Incidence and Mortality in the Czech Republic. Klin Onkol. 2010;23:311–324. PubMed

Dusek L, Muzik J, Kubasek M, Koptikova J, Zaloudik J, Vyzula R. Epidemiology of Malignant Tumours in the Czech Republic [online] Masaryk University, Czech Republic; 2005. http://www.svod.cz. Version 7.0 [2007], ISSN 1802 – 8861.

Giovannucci E, Wu K. In: Cancer. Epidemiology and Prevention. 3. Schottenfeld D, Fraumeni J, editor. Oxford University Press, New York; 2006. Cancers of the colon and rectum.

Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC (American Joint Committee on Cancer) Cancer Staging Manual: 6th edition. Springer, New York; 2002.

Edge SB, Byrd DR, Compton CC, Fritéz AG, Greene FL, Trotli A. AJCC (American Joint Committee on Cancer) Cancer Staging Manual: 7th edition. Springer, New York; 2010.

Greene FL, Stewart AK, Norton HJ. New tumor-node-metastatis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol. 2004;22:1778–1784. doi: 10.1200/JCO.2004.07.015. PubMed DOI

Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383–1388. doi: 10.1136/gut.2010.211557. PubMed DOI

Komuro K, Tada M, Tamoto E, Kawakami A, Matsunaga A, Teramoto K, Shindoh G, Takada M, Murakawa K, Kanai M, Kobayashi N, Fujiwara Y, Nishimura N, Hamada J, Ishizu A, Ikeda H, Kondo S, Katoh H, Moriuchi T, Yoshiki T. Right- and Left-Sided Colorectal Cancers Display Distinct Expression Profiles and the Anatomical Stratification Allows a High Accuracy Prediction of Lymph Node Metastasis. J Surg Res. 2005;124:216–224. doi: 10.1016/j.jss.2004.10.009. PubMed DOI

Rodriguez-Bigas MA, Hoff P, Crane CH, In: Hollan-Frei Cancer Medicine. 7. Kufe DW, Bast RC, Hait WN, editor. BC Decker Inc, Hamilton (Ontario); 2006. Carcinoma of the Colon and Rectum; pp. 1369–1391.

Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D, Taylor I, Van Cutsem E, Van de Velde C, Cellini N, Latini P. Scientific Committee. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2) Radiother Oncol. 2009;92:148–163. doi: 10.1016/j.radonc.2009.06.027. PubMed DOI

Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–4625. doi: 10.1200/JCO.2006.06.7629. PubMed DOI

Engels B, Gevaert T, Sermeus A, De Ridder M. Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer. Front Oncol. 2012;2:47. PubMed PMC

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. et al.Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–2686. doi: 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C. PubMed DOI

Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–928. doi: 10.1002/bjs.8702. PubMed DOI

Suárez J, Vera R, Balén E, Gómez M, Arias F, Lera JM, Herrera J, Zazpe C. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis. 2008;10:563–8. doi: 10.1111/j.1463-1318.2007.01424.x. PubMed DOI

Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8:102. doi: 10.1186/1476-4598-8-102. PubMed DOI PMC

Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D’Incalci M, De Placido S, Pepe S. A Specific miRNA Signature Correlates with Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2012;83(4):1113–1119. doi: 10.1016/j.ijrobp.2011.09.030. PubMed DOI

Drebber U, Lay M, Wedemeyer I, Vallböhmer D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP, Odenthal M. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol. 2011;39:409–15. PubMed

Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol. 2006;411:119–34. PubMed

Dweep H, Sticht C, Pandey P, Gretz N. miRWalk - database: prediction of possible miRNA binding sites by “walking” the genes of 3 genomes. J Biomed Inform. 2011;44(5):839–847. doi: 10.1016/j.jbi.2011.05.002. PubMed DOI

Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010;9:96. doi: 10.1186/1476-4598-9-96. PubMed DOI PMC

Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther. 2010;9(8):2265–2275. doi: 10.1158/1535-7163.MCT-10-0061. PubMed DOI

Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, Andersen CL, Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008;68(24):10094–104. doi: 10.1158/0008-5472.CAN-08-1569. PubMed DOI PMC

Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R, Slaby O. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med. 2012. in press. PubMed PMC

Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K, Ju J. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer. 2011;10(4):340–347. doi: 10.1016/j.clcc.2011.06.002. PubMed DOI PMC

Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007;67(23):11111–11116. doi: 10.1158/0008-5472.CAN-07-2858. PubMed DOI PMC

Bandres E, Arias F, Guerrero D, Lopes I, Gonzalez-Huariz M, Dorronsoro MLG, Montes M, Monzon F, Torrea N, Armendariz P, Balen E, Viudez A, Asin G, Chicata V, Hernandez I, Eito C, Garcia-Foncillas J. Association between a specific miRNA signature and pathological response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) patients. J Clin Oncol. 2012;30(Suppl abstr):e14057. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96385.

Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol. 2011;22:898–905. doi: 10.1016/j.semcdb.2011.07.019. PubMed DOI

Connolly K, Mitter R, Muir M, Jodrell D, Guichard S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol. 2009;64(2):307–316. doi: 10.1007/s00280-008-0872-x. PubMed DOI

Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, Svoboda M, Dolezelova H, Smrcka M, Vyzula R, Michalek J, Hajduch M, Slaby O. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. 2011;102(12):2186–2190. doi: 10.1111/j.1349-7006.2011.02092.x. PubMed DOI PMC

Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy

Translational Potential of MicroRNAs for Preoperative Staging and Prediction of Chemoradiotherapy Response in Rectal Cancer